Anxiety Disorders and Depression Treatment Market

Anxiety Disorders and Depression Treatment Market by Indications (Phobia, Obsessive-compulsive Disorder, Major Depressive Disorder, and Others), Products (Serotonin Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Transcranial Magnetic Stimulation, Valley Beth Shalom, Deep Brain Stimulation, Antidepressant Drugs, Benzodiazepines, Devices & Therapy, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-2454
  • Author: Growth Market Reports
  • Rating: 4.5
  • Total Reviews: 3
  • No. Of Pages: 211
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global anxiety disorders and depression treatment market size is anticipated to register a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the rising prevalence of anxiety disorder and depression globally.

Anxiety Disorders and Depression Treatment Market

Anxiety disorders and depression are two of the most common mental illnesses. They are less obvious than schizophrenia and bipolar disease; yet, they are just as debilitating. The first study took place around 26 years ago by the Epidemiological Catchments Area research program to reveal the extent of their presence. Furthermore, these illnesses have garnered more attention in recent years as a result of their widespread incidence and they are now considered just as important as other syndromes such as mood and psychotic disorders. The primary assessor and treatment provider is the primary care physician. Thus, the market for anxiety disorder and depression treatment is predicted to rise as primary healthcare infrastructure all around the world in the coming years.

According to a survey conducted by Boston University in September 2020, the COVID-19 pandemic had caused half of the adults to show indicators of depression such as thoughts of hopelessness and failure across the globe especially in the US. However, the overall anxiety and depression therapy market has suffered revenue shrinking due to the pandemic. Global lockdowns imposed by government all around the world resulted in factory shutdown and further impacted to the reduction in medication & device production.

Market Trends, Drivers, Restraints, and Opportunities

  • Increasing awareness regarding the anxiety disorder treatments as well as rising availability of specialized doctors and physicians for the treatment are driving the market expansion.
  • Rising R&D programs to provide advanced patient care for mental health disorder and robust drug pipeline are expected to boost the market growth.
  • Ongoing government initiatives to reduce economic burden and cost- effective mental health treatment present key factors propelling the market growth.
  • Prolonged negligence of such children by parents and guardians as well as issues concerning about incorrect treatments and high cost of the treatment are major challenges that can hamper the market growth.
  • Adverse effect of various medication and widening gap between effective treatment & resource availability are key restraining factors hampering the market expansion.  
  • Organizing a series of awareness programs under various initiatives taken by hospitals, medical institutes, and clinics to educate people about the mental health are encouraging the adoption of the treatment. This is expected to fuel the market growth.

Scope of the Report

The report on the global anxiety disorders and depression treatment market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Anxiety Disorders and Depression Treatment Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Indications (Phobia, Obsessive-compulsive Disorder Major Depressive Disorder, and Others) and Products (Serotonin Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Transcranial Magnetic Stimulation, Valley Beth Shalom, Deep Brain Stimulation, Antidepressant Drugs, Benzodiazepines, Devices & Therapy, and Others)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Forest Laboratories, Inc.; Pfizer, Inc.; Eli Lilly and Co.; H. Lundbeck A/S; Sanofi-Aventis; Merck & Co. Inc.; Johnson & Johnson; GlaxoSmithKline plc; and AstraZeneca.

Market Segment Insights

Major depressive disorder segment is expected to grow at a robust growth rate

Based on indications, the global anxiety disorders and depression treatment market is segmented into phobia, obsessive-compulsive disorder (OCD), major depressive disorder, and others. The major depressive disorder segment is expected to grow at a robust growth rate during the forecast period owing to the presence of a large patient base along with the rising implementation of antidepressants to treat these diseases.

Moreover, as per reports by the Anxiety and Depression Association of America, anxiety disorder is the most common mental sickness, impacting millions of adults each year. In addition, current clinical trials for the development of efficient medications as well as future drug commercialization across globe are expected to fuel the segment growth.

Anxiety Disorders and Depression Treatment Market

Antidepressant drugs segment is projected to expand at a considerable CAGR

On the basis of products, the market is segregated as serotonin norepinephrine reuptake inhibitors (SNRIs), selective serotonin reuptake inhibitors (SSRIs), transcranial magnetic stimulation (TMS), valley beth shalom (VBS), deep brain stimulation (DBS), antidepressant drugs, benzodiazepines, devices & therapy, and others. The antidepressant drugs segment is projected to expand at a considerable CAGR during the forecast period. Antidepressant drugs have better efficacy than other medications that helps in reducing the depressive state of mind of an individual. These drugs are often prescribed by neurologist, hospitals, and psychiatrists. Furthermore, rising number of product pipeline candidates along with product approvals are estimated to upsurge the market expansion. Moreover, Janssen Research and Development LLC has initiated the phase III clinical trial of Seltorexant for testing its efficiency for the treatment of depressive disorder.

Anxiety Disorders and Depression Treatment Market

North America is anticipated to constitute a key market share

In terms of regions, the global anxiety disorders and depression treatment market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a key market share during the forecast period owing to the growing incidence of depressive and anxiety disorders, favorable government policies, availability of different branded formulations, and rising awareness levels in the region. On the other hand, Europe held a major share in this market in 2019 and is projected to account for a key market share during the projected period. The growth of the market in the region attributed to the increasing investment in R&D activities for the development of antidepressant drugs and higher products sale for anxiety disorder.

Anxiety Disorders and Depression Treatment Market

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Anxiety Disorders and Depression Treatment Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Anxiety Disorders and Depression Treatment Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Anxiety Disorders and Depression Treatment Market - Supply Chain
  4.5. Global Anxiety Disorders and Depression Treatment Market Forecast
     4.5.1. Anxiety Disorders and Depression Treatment Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Anxiety Disorders and Depression Treatment Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Anxiety Disorders and Depression Treatment Market Absolute $ Opportunity
5. Global Anxiety Disorders and Depression Treatment Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Anxiety Disorders and Depression Treatment Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Anxiety Disorders and Depression Treatment Demand Share Forecast, 2019-2026
6. North America Anxiety Disorders and Depression Treatment Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Anxiety Disorders and Depression Treatment Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Anxiety Disorders and Depression Treatment Demand Share Forecast, 2019-2026
7. Latin America Anxiety Disorders and Depression Treatment Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Anxiety Disorders and Depression Treatment Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Anxiety Disorders and Depression Treatment Demand Share Forecast, 2019-2026
8. Europe Anxiety Disorders and Depression Treatment Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Anxiety Disorders and Depression Treatment Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Anxiety Disorders and Depression Treatment Demand Share Forecast, 2019-2026
9. Asia Pacific Anxiety Disorders and Depression Treatment Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Anxiety Disorders and Depression Treatment Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Anxiety Disorders and Depression Treatment Demand Share Forecast, 2019-2026
10. Middle East & Africa Anxiety Disorders and Depression Treatment Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Anxiety Disorders and Depression Treatment Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Anxiety Disorders and Depression Treatment Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Anxiety Disorders and Depression Treatment Market: Market Share Analysis
  11.2. Anxiety Disorders and Depression Treatment Distributors and Customers
  11.3. Anxiety Disorders and Depression Treatment Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)

Segments Covered in the Report

The global anxiety disorders and depression treatment market has been segmented on the basis of

Indications

  • Phobia
  • Obsessive-compulsive Disorder (OCD)
  • Major Depressive Disorder (MDD)
  • Others

Products

  • Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
  • Selective Serotonin Reuptake Inhibitors (SSRIs)
  • Transcranial Magnetic Stimulation (TMS)
  • Valley Beth Shalom (VBS)
  • Deep Brain Stimulation (DBS)
  • Antidepressant Drugs
  • Benzodiazepines
  • Devices & Therapy
  • Others

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Forest Laboratories, Inc.
  • Pfizer, Inc.
  • Eli Lilly and Co.
  • H. Lundbeck A/S
  • Sanofi-Aventis
  • Merck & Co. Inc.
  • Johnson & Johnson
  • GlaxoSmithKline plc
  • AstraZeneca

Some of the major player competing in the market are Forest Laboratories, Inc.; Pfizer, Inc.; Eli Lilly and Co.; H. Lundbeck A/S; Sanofi-Aventis; Merck & Co. Inc.; Johnson & Johnson; GlaxoSmithKline plc; and AstraZeneca. Many of these major companies are involved in developing new treatments and innovative know sessions to bolster their position in the market. Furthermore, to produce an effective treatment and stay competitive, industry participants are employing competitive tactics such as mergers and acquisitions, distribution channel enhancement, new product creation, and research and development alliances.

Cadent Therapeutics announced that Novartis had planned to acquire the former company for a deal of USD 770 million in December 2020. Through the deal, Novartis would be able to access to right to use Cadent's full neuroscience portfolio and expand its mental health presence as a result of the acquisition. In another event, Big Rock Partners Acquisition Corp. and NeuroRx, a leading developer of innovative medicines for bipolar disorder and COVID-19, signed a merger agreement in December 2020. These are the latest development of major players that helps to expand the overall market growth.

Anxiety Disorders and Depression Treatment Market

Buy Report